Janina Kleymann, Sascha Brückmann, Simona Langner, Dirk Koschel, Martin Kolditz
{"title":"经支气管钳活检诊断COVID-19相关弥漫性肺实质异常","authors":"Janina Kleymann, Sascha Brückmann, Simona Langner, Dirk Koschel, Martin Kolditz","doi":"10.1186/s12890-024-03449-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>The role of lung biopsy for evaluation of persistent chest radiographic abnormalities including secondary organizing pneumonia (OP) in COVID-19 remains uncertain. This study aimed to evaluate the diagnostic value of trans-bronchial forceps biopsy (TBFB) in patients with persistent lung abnormalities on thoracic computed tomography (CT) scan following SARS-CoV-2 infection with particular focus on cases with OP and immunocompromised (IC) patients.</p><p><strong>Methods: </strong>Descriptive retrospective single center analysis of all TBFB performed for diffuse lung parenchymal changes after COVID-19 03-2020 to 06-2023.</p><p><strong>Results: </strong>Twenty seven consecutive TBFB including 23 in IC patients resulted in 100% samples with alveolar tissue showing a high frequency of 12/27 (44%) histological pattern of OP. Steroids were used in 21/27 patients (78%) including 11/12 (92%) with OP. Clinical outcome at discharge was favorable in 89% (92% with OP).</p><p><strong>Conclusion: </strong>TBFB contributes to the diagnosis of diffuse parenchymal lung abnormalities in the context of COVID-19 including a frequent OP pattern particularly in IC patients. Larger studies are necessary to confirm our data and elucidate on the optimal steroid treatment modality.</p><p><strong>Trial registration: </strong>Clinical trial number: not applicable. The study was approved by the Ethics Committee of the University Medicine Carl Gustav Carus, TU Dresden (BO-EK-309072023). Waiver of informed consent was granted because of the retrospective nature of the study.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"24 1","pages":"631"},"PeriodicalIF":2.6000,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11667939/pdf/","citationCount":"0","resultStr":"{\"title\":\"Trans-bronchial forceps biopsy for COVID-19 related diffuse parenchymal lung abnormalities.\",\"authors\":\"Janina Kleymann, Sascha Brückmann, Simona Langner, Dirk Koschel, Martin Kolditz\",\"doi\":\"10.1186/s12890-024-03449-0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>The role of lung biopsy for evaluation of persistent chest radiographic abnormalities including secondary organizing pneumonia (OP) in COVID-19 remains uncertain. This study aimed to evaluate the diagnostic value of trans-bronchial forceps biopsy (TBFB) in patients with persistent lung abnormalities on thoracic computed tomography (CT) scan following SARS-CoV-2 infection with particular focus on cases with OP and immunocompromised (IC) patients.</p><p><strong>Methods: </strong>Descriptive retrospective single center analysis of all TBFB performed for diffuse lung parenchymal changes after COVID-19 03-2020 to 06-2023.</p><p><strong>Results: </strong>Twenty seven consecutive TBFB including 23 in IC patients resulted in 100% samples with alveolar tissue showing a high frequency of 12/27 (44%) histological pattern of OP. Steroids were used in 21/27 patients (78%) including 11/12 (92%) with OP. Clinical outcome at discharge was favorable in 89% (92% with OP).</p><p><strong>Conclusion: </strong>TBFB contributes to the diagnosis of diffuse parenchymal lung abnormalities in the context of COVID-19 including a frequent OP pattern particularly in IC patients. Larger studies are necessary to confirm our data and elucidate on the optimal steroid treatment modality.</p><p><strong>Trial registration: </strong>Clinical trial number: not applicable. The study was approved by the Ethics Committee of the University Medicine Carl Gustav Carus, TU Dresden (BO-EK-309072023). Waiver of informed consent was granted because of the retrospective nature of the study.</p>\",\"PeriodicalId\":9148,\"journal\":{\"name\":\"BMC Pulmonary Medicine\",\"volume\":\"24 1\",\"pages\":\"631\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2024-12-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11667939/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMC Pulmonary Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s12890-024-03449-0\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Pulmonary Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12890-024-03449-0","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0
摘要
目的:肺活检在评估COVID-19患者继发性组织性肺炎(OP)等持续性胸片异常中的作用尚不确定。本研究旨在评估经支气管钳活检(TBFB)对SARS-CoV-2感染后胸部计算机断层扫描(CT)持续肺部异常患者的诊断价值,特别关注OP和免疫功能低下(IC)患者。方法:描述性回顾性单中心分析2019冠状病毒病(COVID-19)后弥漫性肺实质改变的所有TBFB。结果:27例连续TBFB,包括23例IC患者,100%的肺泡组织样本显示12/27(44%)高频率的OP组织学模式。21/27例(78%)患者使用类固醇,其中11/12例(92%)为OP。出院时临床结果良好,89%(92%)为OP。结论:TBFB有助于诊断COVID-19的弥漫性肺实质异常,包括频繁的OP模式,特别是在IC患者中。需要更大规模的研究来证实我们的数据并阐明最佳的类固醇治疗方式。试验注册:临床试验编号:不适用。该研究得到德累斯顿工业大学Carl Gustav Carus医学伦理委员会(BO-EK-309072023)的批准。由于该研究的回顾性性质,我们同意放弃知情同意。
Trans-bronchial forceps biopsy for COVID-19 related diffuse parenchymal lung abnormalities.
Purpose: The role of lung biopsy for evaluation of persistent chest radiographic abnormalities including secondary organizing pneumonia (OP) in COVID-19 remains uncertain. This study aimed to evaluate the diagnostic value of trans-bronchial forceps biopsy (TBFB) in patients with persistent lung abnormalities on thoracic computed tomography (CT) scan following SARS-CoV-2 infection with particular focus on cases with OP and immunocompromised (IC) patients.
Methods: Descriptive retrospective single center analysis of all TBFB performed for diffuse lung parenchymal changes after COVID-19 03-2020 to 06-2023.
Results: Twenty seven consecutive TBFB including 23 in IC patients resulted in 100% samples with alveolar tissue showing a high frequency of 12/27 (44%) histological pattern of OP. Steroids were used in 21/27 patients (78%) including 11/12 (92%) with OP. Clinical outcome at discharge was favorable in 89% (92% with OP).
Conclusion: TBFB contributes to the diagnosis of diffuse parenchymal lung abnormalities in the context of COVID-19 including a frequent OP pattern particularly in IC patients. Larger studies are necessary to confirm our data and elucidate on the optimal steroid treatment modality.
Trial registration: Clinical trial number: not applicable. The study was approved by the Ethics Committee of the University Medicine Carl Gustav Carus, TU Dresden (BO-EK-309072023). Waiver of informed consent was granted because of the retrospective nature of the study.
期刊介绍:
BMC Pulmonary Medicine is an open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of pulmonary and associated disorders, as well as related molecular genetics, pathophysiology, and epidemiology.